| Literature DB >> 27992552 |
Neily Zakiyah1, Antoinette D I van Asselt1,2, Frank Roijmans3, Maarten J Postma1,2,4.
Abstract
BACKGROUND: A significant number of women in low and middle income countries (L-MICs) who need any family planning, experience a lack in access to modern effective methods. This study was conducted to review potential cost effectiveness of scaling up family planning interventions in these regions from the published literatures and assess their implication for policy and future research. STUDYEntities:
Mesh:
Year: 2016 PMID: 27992552 PMCID: PMC5167385 DOI: 10.1371/journal.pone.0168447
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Characteristics of the included studies.
| 1 | Hu D, et al [ | 2007 | Mexico | The Costs, Benefits, and Cost-Effectiveness of Interventions to Reduce Maternal Morbidity and Mortality in Mexico | Single country | CEA & CUA | AMRO | Upper-middle income | John D and Catherine T MacArthur Foundation |
| 2 | Goldie SJ, et al [ | 2010 | India | Alternative Strategies to Reduce Maternal Mortality in India: A Cost-Effectiveness Analysis | Single country | CEA | SEARO | Lower-middle income | John D and Catherine T MacArthur Foundation |
| 3 | Carvalho N, et al [ | 2013 | Afghanistan | National and Sub-national Analysis of the Health Benefits and Cost Effectiveness of Strategies to Reduce Maternal Mortality in Afghanistan | Single country | CEA | EMRO | Low-income | John D and Catherine T MacArthur Foundation |
| 4 | Erim, et al [ | 2012 | Nigeria | Assessing Health and Economic Outcomes of Interventions to Reduce Pregnancy-Related Mortality in Nigeria | Single country | CEA | AFRO | Lower-middle income | John D and Catherine T MacArthur Foundation |
| 5 | Babigumira JB, et al [ | 2012 | Uganda | Potential Cost-Effectiveness of Universal Access to Modern Contraceptives in Uganda | Single country | CEA & CUA | AFRO | Low-income | William and Flora Hawlett Foundation |
| 6 | Kennedy EC, et al [ | 2013 | Vanuatu and Solomon Islands | The Case for Investing in Family Planning in the Pacific: Costs and Benefits of Reducing Unmet Need for Contraception in Vanuatu and the Solomon Islands | Multi-country | CEA | WPRO | Lower-middle income | None stated |
| 7 | Reynolds HW, et al [ | 2006 | Sub-Saharan Africa | The Value of Contraception to Prevent Perinatal HIV Transmission | Multi-country | CEA | AFRO | Mixed (low-income—upper middle-income) | USAID |
| 8 | Halperin DT, et al [ | 2009 | 14 countries in Africa | Benefits and Costs of Expanding Access to Family Planning Programs to Women Living with HIV | Multi-country | CBA | Multiple | Mixed (low-income—upper middle-income) | USAID |
| 9 | Shade SB, et al [ | 2013 | Kenya | Cost, Cost-efficiency and Cost-Effectiveness of Integrated Family Planning and HIV Services | Single country | CEA | AFRO | Low-income | The Bill & Melinda Gates Foundation |
CEA: Cost effectiveness analysis
CUA: Cost utility analysis
CBA: Cost benefit analysis
AMRO: Regional office for the Americas
SEARO: Regional office for South-East Asia
EMRO: Regional office for the Eastern Mediterranean
AFRO: Regional office for Africa
WPRO: Regional Office for the Western Pacific
USAID: United States Agency for International Development
Methodological characteristics and results of the included studies.
| 1 | Increasing FP coverage up to 74% (older than 20 years old) and 33% (younger than 20 years old) and improving maternal care | Oral contraceptives, IUD, injectables, condoms, female and male sterilization | Current standard of care (existing coverage of modern FP: 59% in women older than 20 years old, 18% for women younger than 20 years old) | Decision tree | GDP/capita (8,118) | Lifetime | Univariate | ICER per DALY averted | 401 | Moderate | [ |
| 2 | Stepwise approach to reduce the unmet need by 25%, 50%, 75% until 100%; and improving maternal care | Oral contraceptives, IUD, injectables, condoms, female and male sterilization | Current standard of care (existing coverage of modern FP: 48.5%, unmet need: 13.2%) | Computer-based Global Maternal Health Policy Model | GDP/capita (1,253) | Lifetime | Univariate (one-way) | ICER per YLS | 587 | Good | [ |
| 3 | Increasing FP coverage up to 30%-60% and improving maternal care | Oral contraceptives, IUD, injectables, condoms, female and male sterilization, traditional methods | Current standard of care (existing coverage of FP any method: 23%) | Computer-based Global Maternal Health Policy Model | GDP/capita (587) | Lifetime | Univariate | ICER per YLS | 235 | Good | [ |
| 4 | Stepwise approach to reduce the unmet need by 25%, 50%, 75% until 100%; and improving maternal care | Oral contraceptives, IUD, injectables, condoms, female and male sterilization | Current standard of care (existing coverage of modern FP: 9.7%, unmet need: 20.2%) | Computer-based Global Maternal Health Policy Model | GDP/ capita (1,285) | Lifetime | Univariate | ICER per YLS | 550 | Good | [ |
| 5 | New contraceptive program to reduce the unmet need by 100% (universal access to modern contraceptives) | Oral contraceptives, IUD, injectables, condoms, implants, female and male sterilization | Current contraceptive program (existing coverage of modern FP: 31%) | Markov | GDP/ capita (515) | Lifetime | Univariate & probabilistic | ICER per YLS and per DALY | Dominant | Good | [ |
| 6 | Two scenarios: 1) all family planning needs (100%) met by 2020; and, 2) all needs met by 2050. | Oral contraceptives, IUD, injectables, condoms, implants, female and male sterilization, traditional methods | No change in unmet need for FP (existing unmet need: Vanuatu 30%; Solomon Islands 11%) | Demographic modelling | NA | 5–15 years | Univariate (one-way) | Cost per unintended pregnancy averted | Solomon: 1) 1102) 153 Vanuatu: 1)1142) 154 | Moderate | [ |
| 7 | Increasing FP coverage to reduce the unmet need by 90% | Oral contraceptives, IUD, injectables, condoms, implants, female and male sterilization | Improved access to HIV testing and counseling, coupled with Nevirapine for PMTCT | Decision tree | NA | 1 year | One-way | ICER per HIV-positive birth averted | 886 | Moderate | [ |
| 8 | Increasing FP coverage to reduce the unmet need by 100%; for women with HIV | Oral contraceptives, IUD, injectables, condoms, implants, female and male sterilization | Current situation (no change in unmet need for FP) | Cost projection | NA | NA | NR | ICER per infant HIV infections averted | 390 | Low | [ |
| 9 | Integrated family planning services with HIV care and treatment. | Oral contraceptives, IUD, injectables, condoms, implants, female and male sterilization | Standard care of HIV care with separate family planning and HIV services | Trial-based cost effectiveness | NA | 1 year | NR | ICER per unintended pregnancy averted | 1439 | Moderate | [ |
* Identical economic model
** Intervention is less costly and more effective compared to comparator
FP: family planning
IUD: intrauterine devices
NR: Not Reported
NA: Not applicable
GDP: Gross Domestic Product
PMTCT: Prevention of mother to child transmission of HIV
ICER: Incremental cost effectiveness ratio
DALY: Disability adjusted life year
YLS: Year of life saved
Fig 1PRISMA flow diagram depicting the process of the study selection.
Perspective and category of included costs.
| Study | Perspective | Cost year and currency | Discount rates | Cost breakdown | |||||
|---|---|---|---|---|---|---|---|---|---|
| Cost | Outcomes | Direct costs | Indirect costs | Source of costs | |||||
| Family planning costs | Pregnancy-related costs | Other costs | |||||||
| [ | NR | USD 2001 | NR | NR | Modern contraceptives | Abortion, prenatal care, delivery, preeclampsia/ eclampsia, sepsis obstructed labor, postpartum hemorrhage, postnatal care | Severe anemia, sexually transmitted infection | NA | Secondary data |
| [ | NR | USD 2006 | 3% | NR | Modern contraceptives | Abortion, antenatal care, delivery, community-based interventions, management of complications, postpartum care | Transportation | NA | Secondary data |
| [ | NR | USD 2006 | NR | NR | Modern & traditional contraceptives | Abortion, antenatal care, delivery, community-based interventions, management of complications, postpartum care | Transportation | NA | Secondary data |
| [ | Societal | USD 2008 | NR | NR | Modern contraceptives | Abortion, antenatal care, delivery, community-based interventions, management of complications, postpartum care | Transportation | NR | Secondary data |
| [ | Societal & governmental | USD 2010 | 3% | 3% | Modern contraceptives | Antenatal care, miscarriage, induced abortion, ectopic pregnancy, delivery, obstetric hemorrhage, eclampsia | Overhead and capital costs associated with different services | Productivity loss | Secondary data |
| [ | Healthcare provider (service delivery) | USD 2010 | 3% | 3% | Modern & traditional contraceptives | NA | Transportation, storage | NA | Secondary data |
| [ | Healthcare provider (service delivery) | USD 2000 | NA | NA | Modern contraceptives | NA | PMTCT including drugs, personnel, counseling and testing | NA | Secondary data |
| [ | Healthcare provider (service delivery) | Price year not mentioned | NR | NR | Modern contraceptives | NA | Antiretroviral | NA | Secondary data |
| [ | NR | USD 2011 | NA | NA | Integration of modern contraceptives | NA | Counseling, training | NA | Primary data |
IUD = Intrauterine device
PMTCT = Prevention of mother-to-child transmission
a Modern contraceptives including oral contraceptives, injectable contraceptives, barrier contraceptives, intrauterine device, female and male sterilization weighted by the costs of healthcare personnel and services
b Including costs of healthcare personnel and other healthcare materials
CHEERS checklist per item for all included studies in the review.
| CHEERS section/item | Item No | References | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| [ | [ | [ | [ | [ | [ | [ | [ | [ | ||
| Title | 1 | Y | Y | Y | Y | Y | Y | N | Y | Y |
| Abstract | 2 | Y | Y | Y | Y | Y | Y | P | P | P |
| Background and objectives | 3 | Y | Y | Y | Y | Y | Y | P | Y | Y |
| Target population and subgroups | 4 | Y | Y | Y | Y | Y | Y | Y | Y | Y |
| Setting and location | 5 | Y | Y | Y | Y | Y | Y | Y | Y | Y |
| Study perspective | 6 | N | N | N | Y | Y | Y | Y | Y | N |
| Comparators | 7 | Y | Y | Y | Y | Y | Y | P | NA | Y |
| Time horizon | 8 | Y | Y | Y | Y | Y | P | Y | N | N |
| Discount rate | 9 | N | P | N | N | Y | Y | NA | N | N |
| Choice of health outcomes | 10 | Y | Y | Y | Y | Y | P | Y | P | P |
| Measurement of effectiveness (single study-based estimates) | 11a | NA | NA | NA | NA | NA | NA | NA | N | P |
| Measurement of effectiveness (synthesis-based estimates) | 11b | P | P | P | P | Y | P | P | P | NA |
| Measurement and valuation of preference based outcomes | 12 | Y | Y | Y | Y | Y | NA | N | NA | P |
| Estimating resources and costs (single study-based economic evaluation) | 13a | NA | NA | NA | NA | NA | NA | NA | NA | P |
| Estimating resources and costs (model-based economic evaluation) | 13b | P | P | P | P | P | Y | P | P | NA |
| Currency, price date, and conversion | 14 | Y | Y | Y | Y | Y | Y | Y | N | Y |
| Choice of model | 15 | Y | Y | Y | Y | Y | P | P | N | NA |
| Assumptions | 16 | Y | Y | Y | Y | Y | Y | Y | N | N |
| Analytical methods | 17 | P | P | P | P | P | P | P | P | P |
| Study parameters | 18 | Y | Y | Y | Y | Y | P | Y | P | Y |
| Incremental costs and outcomes | 19 | Y | Y | Y | Y | Y | P | Y | P | Y |
| Characterizing uncertainty (single study-based economic evaluation) | 20a | NA | NA | NA | NA | NA | NA | NA | NA | N |
| Characterizing uncertainty (model-based economic evaluation) | 20b | P | Y | P | Y | Y | P | Y | N | NA |
| Characterising heterogeneity | 21 | NA | NA | NA | NA | NA | NA | NA | NA | N |
| Study findings, limitations, generalizability, and current knowledge | 22 | Y | Y | Y | Y | Y | P | P | P | P |
| Source of funding | 23 | N | N | Y | Y | Y | N | Y | N | Y |
| Conflict of interest | 24 | N | N | Y | Y | Y | N | N | Y | Y |
| Moderate | Good | Good | Good | Good | Moderate | Moderate | Low | Moderate | ||
Yes: reported, Part: partially reported, No: not reported, NA: not applicable
*Studies were assigned 1 point per item for Yes, 0.5 for part, and 0 for No. Percentage score was calculated after the exclusion of “not applicable” item